Wave Life Sciences has initiated a Phase 1 clinical trial, INLIGHT, for WVE-007, a novel RNA interference (RNAi) therapy targeting obesity. WVE-007, administered as a long-acting GalNAc-siRNA, targets INHBE mRNA, which encodes a protein that inhibits fat burning. The company anticipates releasing proof-of-concept data from the trial in 2025.
This development is potentially groundbreaking for the obesity treatment landscape. Current therapies often struggle to achieve substantial, sustainable weight loss while preserving lean muscle mass. WVE-007’s mechanism, focused on directly influencing fat cell metabolism, offers a unique approach that could address these challenges. The potential for infrequent dosing (once or twice yearly) further differentiates it, potentially improving patient adherence and long-term outcomes. This approach could significantly impact the lives of over a billion individuals globally affected by obesity, offering a new avenue for effective and convenient weight management.
The INLIGHT trial will evaluate WVE-007’s safety, tolerability, pharmacokinetics, and efficacy in adults with overweight or obesity. The study will measure biomarkers for target engagement, body weight and composition changes, and metabolic health improvements. The focus on fat loss while preserving lean mass aligns with recent FDA guidance on weight-loss therapeutics. WVE-007’s preclinical data suggests its potential as a monotherapy, in combination with GLP-1 receptor agonists, and as a maintenance therapy to prevent weight regain after discontinuing GLP-1 treatment.
The commencement of the INLIGHT trial marks a significant milestone for Wave Life Sciences, representing their first siRNA therapy to enter clinical development. Positive results from this trial could validate their RNAi platform and pave the way for future applications in addressing other common diseases. The data expected in 2025 will be critical in determining the future development trajectory of WVE-007 and its potential to reshape the obesity treatment paradigm.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
